English

OnKure Therapeutics, Inc.

EDGAR

OKUR Quarterly report (10-Q) · filed 2026-08-04

Annual consolidated revenue for 2024: about USD 0, using the latest reported figures.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

0 USD

2024 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-51.1 million USD

2024 · USD

Exact inputs and evidence

Operating Cash Flow: -51117000 USD Source

Free cash flow

-51.2 million USD

2024 · USD

Exact inputs and evidence

Operating Cash Flow: -51117000 USD Source
Capital Expenditure: 52000 USD Source

Cash and cash equivalents: 167 million USD 2026-06-30 Source
Exact value

166500000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 3.34 million shares 2024-09-30 Source
Exact value

3343525 shares

Reported share-count change

-90.13% · -30.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

33872166 shares · 2023-09-30· Source
3343525 shares · 2024-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-58.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -14699000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -13503000 USD · 2025-10-01 – 2025-12-31 Source
Net income: -15157000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -15346000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-47.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -40316000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -27279000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -51828000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -40316000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12938000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -23292000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12938000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

23 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 31000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 5000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-47.9 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -40316000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -27279000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -51828000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -40316000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12938000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -23292000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12938000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 31000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 46000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 5000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-04.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 1 of 11 periods available· newest 2024-12-31
Operating income: 4 of 11 periods available· newest 2024-12-31
Net income: 4 of 11 periods available· newest 2024-12-31
Operating cash flow: 4 of 11 periods available· newest 2024-12-31
Capital expenditure: 4 of 11 periods available· newest 2024-12-31
Total assets: 1 of 11 periods available· newest 2024-12-31
Total liabilities: 1 of 11 periods available· newest 2024-12-31
Current assets: 1 of 11 periods available· newest 2024-12-31
Current liabilities: 1 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 1 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 17.36 million

Prior period

−USD 35.31 million

2023-01-01 – 2023-12-31
Current period

−USD 52.67 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-52673000 − -35311000 = -17362000 USD

-35311000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-52673000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Year-over-year change in Net income: -17362000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -52673000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2437651 Filing: 000119312526104147 Input fundies:NetIncome: -35311000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2065386 Filing: 000095017025036252
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 16.57 million

Prior period

−USD 34.55 million

2023-01-01 – 2023-12-31
Current period

−USD 51.12 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-51117000 − -34546000 = -16571000 USD

-34546000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-51117000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Year-over-year change in Operating cash flow: -16571000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -51117000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2178333 Filing: 000119312526104147 Input fundies:OperatingCashFlow: -34546000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2102127 Filing: 000095017025036252
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-78.9%

Prior period

USD 246,000

2023-01-01 – 2023-12-31
Current period

USD 52,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

52000 − 246000 = -194000 USD

246000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
52000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Year-over-year change in Capital expenditure: -194000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 52000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2187661 Filing: 000119312526104147 Input fundies:CapitalExpenditure: 246000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2110825 Filing: 000095017025036252
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 0
Operating costs Derived USD 54.39 million
Operating income −USD 54.39 million
Tax, interest and other Derived −USD 1.71 million
Net income −USD 52.67 million

Cash

Operating cash flow −USD 51.12 million
Capital expenditure USD 52,000
Free cash flow Derived −USD 51.17 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2024 2024-01-01 – 2024-12-31	0	54386000 Derived	-54386000	-1713000 Derived	-52673000	-51169000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -54386000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -52673000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -51117000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 52000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Operating margin	Not reported	Operating Income: -54386000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -52673000 Open source Revenue: 0 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -51117000 Open source Capital Expenditure: 52000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -51.1M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Operating cash flow	-51117000	Operating Cash Flow: -51117000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -51.2M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20242024-12-31	Free cash flow	-51169000	Operating Cash Flow: -51117000 Open source Capital Expenditure: 52000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

9.6% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Liabilities / assets	9.6%	Total Liabilities: 11079000 Open source Total Assets: 114907000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.73× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20242024-12-31	Current assets / current liabilities	10.73×	Current Assets: 113003000 Open source Current Liabilities: 10530000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2021 2021-01-01 – 2021-12-31	−USD 39.77 million Exact value Exact value: -39770000 USD 2021-01-01 – 2021-12-31: -39770000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OnKure Therapeutics, Inc. · 2021-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Net Income: -39770000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -39770000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009978/rphm-20221231.htm#2016811 Filing: 000095017023009978 The citation records this snapshot. The page link may show a newer release later.	−USD 37.98 million Exact value Exact value: -37983000 USD 2021-01-01 – 2021-12-31: -37983000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OnKure Therapeutics, Inc. · 2021-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Operating Cash Flow: -37983000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -37983000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009978/rphm-20221231.htm#2071893 Filing: 000095017023009978 The citation records this snapshot. The page link may show a newer release later.	USD 198,000 Exact value Exact value: 198000 USD 2021-01-01 – 2021-12-31: 198000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OnKure Therapeutics, Inc. · 2021-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Capital Expenditure: 198000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 198000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009978/rphm-20221231.htm#2079823 Filing: 000095017023009978 The citation records this snapshot. The page link may show a newer release later.	−USD 38.18 million Calculation and evidence -37983000 − 198000 USD Exact free cash flow: -38181000 USD 2021-01-01 – 2021-12-31: -37983000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 198000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OnKure Therapeutics, Inc. · 2021-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Free cash flow: -38181000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37983000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009978/rphm-20221231.htm#2071893 Filing: 000095017023009978 Input fundies:CapitalExpenditure: 198000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009978/rphm-20221231.htm#2079823 Filing: 000095017023009978 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 29.51 million Exact value Exact value: -29512000 USD 2022-01-01 – 2022-12-31: -29512000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OnKure Therapeutics, Inc. · 2022-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Net Income: -29512000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29512000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714ds1.htm#2228031 Filing: 000119312524241926 The citation records this snapshot. The page link may show a newer release later.	−USD 26.95 million Exact value Exact value: -26953000 USD 2022-01-01 – 2022-12-31: -26953000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OnKure Therapeutics, Inc. · 2022-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Operating Cash Flow: -26953000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26953000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714ds1.htm#2241715 Filing: 000119312524241926 The citation records this snapshot. The page link may show a newer release later.	USD 1.13 million Exact value Exact value: 1134000 USD 2022-01-01 – 2022-12-31: 1134000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OnKure Therapeutics, Inc. · 2022-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Capital Expenditure: 1134000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1134000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714ds1.htm#2245455 Filing: 000119312524241926 The citation records this snapshot. The page link may show a newer release later.	−USD 28.09 million Calculation and evidence -26953000 − 1134000 USD Exact free cash flow: -28087000 USD 2022-01-01 – 2022-12-31: -26953000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1134000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OnKure Therapeutics, Inc. · 2022-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Free cash flow: -28087000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26953000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714ds1.htm#2241715 Filing: 000119312524241926 Input fundies:CapitalExpenditure: 1134000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714ds1.htm#2245455 Filing: 000119312524241926 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 35.31 million Exact value Exact value: -35311000 USD 2023-01-01 – 2023-12-31: -35311000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OnKure Therapeutics, Inc. · 2023-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Net Income: -35311000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35311000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2065386 Filing: 000095017025036252 The citation records this snapshot. The page link may show a newer release later.	−USD 34.55 million Exact value Exact value: -34546000 USD 2023-01-01 – 2023-12-31: -34546000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OnKure Therapeutics, Inc. · 2023-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Operating Cash Flow: -34546000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34546000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2102127 Filing: 000095017025036252 The citation records this snapshot. The page link may show a newer release later.	USD 246,000 Exact value Exact value: 246000 USD 2023-01-01 – 2023-12-31: 246000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OnKure Therapeutics, Inc. · 2023-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Capital Expenditure: 246000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 246000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2110825 Filing: 000095017025036252 The citation records this snapshot. The page link may show a newer release later.	−USD 34.79 million Calculation and evidence -34546000 − 246000 USD Exact free cash flow: -34792000 USD 2023-01-01 – 2023-12-31: -34546000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 246000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OnKure Therapeutics, Inc. · 2023-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Free cash flow: -34792000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34546000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2102127 Filing: 000095017025036252 Input fundies:CapitalExpenditure: 246000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-20241231.htm#2110825 Filing: 000095017025036252 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 52.67 million Exact value Exact value: -52673000 USD 2024-01-01 – 2024-12-31: -52673000 USD Inspect Net Income Open source Share or cite Citation for Net Income · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Net Income: -52673000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52673000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2437651 Filing: 000119312526104147 The citation records this snapshot. The page link may show a newer release later.	−USD 51.12 million Exact value Exact value: -51117000 USD 2024-01-01 – 2024-12-31: -51117000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Operating Cash Flow: -51117000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -51117000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2178333 Filing: 000119312526104147 The citation records this snapshot. The page link may show a newer release later.	USD 52,000 Exact value Exact value: 52000 USD 2024-01-01 – 2024-12-31: 52000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Capital Expenditure: 52000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2187661 Filing: 000119312526104147 The citation records this snapshot. The page link may show a newer release later.	−USD 51.17 million Calculation and evidence -51117000 − 52000 USD Exact free cash flow: -51169000 USD 2024-01-01 – 2024-12-31: -51117000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 52000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · OnKure Therapeutics, Inc. · 2024-12-31 OnKure Therapeutics, Inc. (edgar:1637715) Free cash flow: -51169000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:56:02Z Snapshot: ba464c3f7ff18a78864dd48137609a6e7074ed8214fa2e96595659e50113a8bb Dimensions: Consolidated View: https://fundies.io/companies/edgar/1637715?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -51117000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2178333 Filing: 000119312526104147 Input fundies:CapitalExpenditure: 52000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-20251231.htm#2187661 Filing: 000119312526104147 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

32 filings · 1,530 latest values · 1,530 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001637715, 1637715, OKUR, RPHM, edgar:1637715

Also known as ONKURE THERAPEUTICS, INC., OnKure Therapeutics, Inc., RENEO PHARMACEUTICALS, INC., Reneo Pharmaceuticals, Inc.

OnKure Therapeutics, Inc.

Latest fiscal year

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation